glp-1 agonists cardiovascular diseases Frontiers Cardiovascular Protective Properties of GLP-1
Description
2022, doi: 10.1001/jamainternmed.2022.3810
However, clinical evidence of GIP receptor engagement is still lacking and due to similar actions of GIP and GLP-1 receptor activation, the distinct mode of action for this dual-acting compound is complex to address (41)
Gallagher AM, Dedman D, Padmanabhan S, Leufkens HGM, de Vries F
Neuroprotective Effects of the Novel GLP-1 Long Acting Analogue Semaglutide in the MPTP Parkinsons Disease Mouse Model
The Danish Animal Experiments Inspectorate approved all experiments which were conducted using internationally accepted principles for the use of laboratory animals under the personal license #2013-15-2934-00784
Chang G, Zhang D, Yu H, Zhang P, Wang Y, Zheng A, Qin S: Cardioprotective effects of exenatide against oxidative stress-induced injury
